Methods of treating symptoms of gastroparesis using velusetrag

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 11642339
APP PUB NO 20190030022A1
SERIAL NO

16048933

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The present invention relates to methods and pharmaceutical compositions for treatment of all symptoms of gastroparesis in a human patient, the method comprising administering to the human patient between about 0.5 mg/day to about 30 mg/day, about 0.5 mg/day to about 15 mg/day, about 0.5 mg/day to about 5 mg/day, or about 5 mg/day, of velusetrag or a pharmaceutically-acceptable salt thereof.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

  • THERAVANCE BIOPHARMA R&D IP, LLC; ALFASIGMA S.P.A.

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Barnes, Christopher Noel San Francisco, US 5 1
Grimaldi, Maria Bologna, IT 8 12
Renzulli, Cecilia Bologna, IT 3 2
Viscomi, Giuseppe Claudio Bologna, IT 82 622

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
3.5 Year Payment $1600.00 $800.00 $400.00 Nov 9, 2026
7.5 Year Payment $3600.00 $1800.00 $900.00 Nov 9, 2030
11.5 Year Payment $7400.00 $3700.00 $1850.00 Nov 9, 2034
Fee Large entity fee small entity fee micro entity fee
Surcharge - 3.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00